Print

Merck KGaA (MKGAF.PK) MS Pill Cladribine Rejected by European Medicines Evaluation Agency  
9/24/2010 6:47:55 AM

FRANKFURT, Sept 24 (Reuters) - European regulators dealt Merck KGaA (MRCG.DE) a major blow by recommending against its biggest pipeline drug, multiple sclerosis (MS) pill cladribine, adding to a string of setbacks at the company's drugs unit.
//-->